Hospital mortality in COVID-19 patients in Belgium treated with statins, ACE inhibitors and/or ARBs
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2021.03.24.21252687: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: The ethics committees of the four hospitals gave their approvals for the study. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
No key resources detected.
Results from OddPub: Thank you for sharing your data.
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Our observational study has several limitations. The sample size (959 patients) was small; our findings will need to be replicated in larger studies. We could not evaluate separately the effects of ACEI and ARB treatment, although investigators have reported …
SciScore for 10.1101/2021.03.24.21252687: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: The ethics committees of the four hospitals gave their approvals for the study. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
No key resources detected.
Results from OddPub: Thank you for sharing your data.
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Our observational study has several limitations. The sample size (959 patients) was small; our findings will need to be replicated in larger studies. We could not evaluate separately the effects of ACEI and ARB treatment, although investigators have reported greater effectiveness for ACEI compared with ARB treatment [94]. We did not correct for immortal time bias. We did not have access to information on outpatient treatments and thus could not evaluate whether outpatient statin treatment was continued in the hospital or initiated only after hospital admission. We could not evaluate deaths that occurred after 28 days or that might have occurred after hospital discharge. We also did not evaluate the effects of treatment on length of stay, ICU admissions or mechanical ventilation. We are currently expanding our study to include the second pandemic wave (1 August to 31 December 2020) and additional outcomes (e.g., ICU admissions, mechanical ventilation). We will also evaluate separately the contributions of ACEI and ARB treatments alone or in combination with statins to reducing in-hospital COVID-19 mortality and their effectiveness in treating asymptomatic (but PCR test-positive) patients. Observational studies and RCTs both have their places in the hierarchy of research designs [95]. However, if there are no RCTs [96], physicians and health officials will be forced to consider the trade-off between pandemic learning and doing [97]. In this circumstance, they might have to rely...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
